Ecnoglutide ECNO

An experimental injectable drug in human trials, mostly in China, for diabetes and obesity. Early results show meaningful blood sugar control and weight loss, but it's still unapproved and awaiting more testing.

Also known as XW003

Effects Lose fat

Routes Subcutaneous

Legal status Unapproved / investigational

WADA Not listed

Molecular Structure of C₁₉₄H₃₀₄N₄₈O₆₁

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C194H304N48O61
Molar mass: 4285
CAS: 2459531-73-6
PubChem CID: 162625103

Reported dosing

Clinical data

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose Not yet approved; trial dosing under evaluation

Reported range Phase II/III trials (China): up to 6 mg once weekly

Route Subcutaneous injection

Frequency Once weekly

Duration Trial durations of up to a year

Investigational GLP-1 receptor agonist in development primarily in China; not approved in the US, so any current supply there is unregulated.

Where this comes from Published Phase II/III clinical trial data

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.